ACCEPT
| Info: | ACCEPT Trial Registration |
| Type: | Diffuse large B cell lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II R-CHOP+acalabrutinib, front-line DLBCL |
ACCEPT
| Info: | ACCEPT Trial Registration |
| Type: | Diffuse large B cell lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II R-CHOP+acalabrutinib, front-line DLBCL |
ACE-LY-110
| Info: | ACE-LY-110 Trial Registration |
| Type: | Diffuse large B cell lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II vistusertib + acalabrutinib in R/R DLBCL |
INCA
| Info: | INCA Trial Registration |
| Type: | Diffuse large B cell lymphoma |
| Centres: | Oxford; Bucks |
| Description: | DLBCL front line, co-morbid, PII |
Maple
| Info: | Maple Trial Registration |
| Type: | Diffuse large B cell lymphoma |
| Centres: | Oxford, Bucks, Milton Keynes |
| Description: | Tissue and data collection project in front line DLBCL |
Unity-NHL
| Info: | Unity-NHL Trial Registration |
| Type: | Diffuse large B cell lymphoma, follicular lymphoma, marginal zone lymphoma, SLL |
| Centres: | Oxford |
| Description: | Phase II umbrelisib + ublituximab +/- bendamustine in R/R NHL – DLBCL, FL, MZL, SLL |
ADCT301-002
| Info: | ADCT301-002 Trial Registration |
| Type: | Hodgkin and non Hodgkin lymphomas |
| Centres: | Oxford |
| Description: | Phase I using ADCT301 in R/R lymphoma |
AVAIL-T
| Info: | AVAIL-T Trial Registration |
| Type: | Relapsed/Refractory Peripheral T-cll Lymphoma (PTCL) |
| Centres: | Oxford |
| Description: | Avelumab in relapsed / refractory PTCL |
ENRICH
| Info: | ENRICH Trial Registration |
| Type: | Mantle Cell lymphoma |
| Centres: | Oxford, Milton Keynes |
| Description: | Ibrutinib and rituximab in front line elderly mantle cell lymphoma |
Mantle cell lymphoma biobank
| Info: | Mantle cell lymphoma biobank Trial Registration |
| Type: | Mantle Cell lymphoma |
| Centres: | Oxford |
| Description: | Biobank study for new diagnosis mantle cell lymphoma |
BeiGene study BGB-3111-302
| Info: | BeiGene study BGB-3111-302 Trial Registration |
| Type: | WM |
| Centres: | Oxford |
| Description: | A randomised phase 2 study of ibrutinib versus BGB-3111 in patients with Waldenstroms macroglobulinaemia |
BI-1206
| Info: | BI-1206 Trial Registration |
| Type: | B-cell NHL, CLL and WM |
| Centres: | Oxford |
| Description: | Phase I/II using an anti-CD32b antibody +/- rituximab in R/R NHL and CLL |
5F9003 trial
| Info: | 5F9003 trial Trial Registration |
| Type: | Non-Hodgkin lymphoma |
| Centres: | Oxford, Milton Keynes |
| Description: | Phase I/II using an anti-CD47 antibody in combination with rituximab in R/R DLBCL and follicular lymphoma. |
Fusion-NHL
| Info: | Fusion-NHL Trial Registration |
| Type: | Non-Hodgkin lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II involving durvalumab combination in R/R NHL |
Javelin-NHL
| Info: | Javelin-NHL Trial Registration |
| Type: | Non-Hodgkin lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II involving avelumab combinations in R/R NHL |
POLARIX
| Info: | POLARIX Trial Registration |
| Type: | Diffuse Large B-Cell Lymphoma |
| Centres: | Oxford |
| Description: | RCHOP vs RCHP + polatuzumab vedotin in front line DLBCL |
RIVA
| Info: | RIVA Trial Registration |
| Type: | Relapsed/refractory B-cell non-Hodgkin Lymphoma |
| Centres: | Oxford |
| Description: | Phase II rituximab + varilumab in R/R NHL |
RomiCar
| Info: | RomiCar Trial Registration |
| Type: | Peripheral T Cell lymphoma |
| Centres: | Oxford |
| Description: | Phase I/II romidepsin and carfilzomib in R/R PTCL |
TIDAL
| Info: | TIDAL Trial Registration |
| Type: | Post transplant Lymphoproliferative disorder (PTLD) |
| Centres: | Oxford |
| Description: | Ibrutinib + Rituximab as first line treatment for PTLD |
TIER
| Info: | TIER Trial Registration |
| Type: | PCNSL |
| Centres: | Oxford |
| Description: | Phase I/II using thiotepa based chemotherapy in R/R PCNSL |
PQR309-002
| Info: | PQR309-002 Trial Registration |
| Type: | All |
| Centres: | Oxford |
| Description: | Phase I/II using PQR309-002 in R/R lymphoma |
PCYC1143 (SYMPATICO)
| Info: | PCYC1143 (SYMPATICO) Trial Registration |
| Type: | Mantle Cell lymphoma |
| Centres: | Oxford |
| Description: | Ibrutinib + Venetoclax vs Ibrutinib + placebo in refractory MCL |